Study on Protective Effects of Glycyrrhiza and Pueraria Fermentation Composition on Rats with Chronic Liver Injury

WANG Jing; LI Fengjuan; ZHANG Huapeng; LIU Jinglan; WU Like

doi:10.13386/j.issn1002-0306.2021110140

Volume 43 Issue 12

Jun. 2022

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2022 > 43(12): 369-376. > DOI: 10.13386/j.issn1002-0306.2021110140

WANG Jing, LI Fengjuan, ZHANG Huapeng, et al. Study on Protective Effects of Glycyrrhiza and Pueraria Fermentation Composition on Rats with Chronic Liver Injury[J]. Science and Technology of Food Industry, 2022, 43(12): 369−376. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2021110140.

Citation:

PDF (3570 KB)

Study on Protective Effects of Glycyrrhiza and Pueraria Fermentation Composition on Rats with Chronic Liver Injury

1.
Shandong Phoenix Biotechnology Co., Ltd., Taian 271000, China
2.
Southwest Hospital of the Third Military Medical University, Chongqing 400038, China

More Information

Received Date: November 14, 2021
Available Online: April 14, 2022

Graphical Abstract

Abstract

Abstract

Objective: To study the protective effect and potential mechanism of glycyrrhiza and pueraria fermentation composition on chronic liver injury induced by carbon tetrachloride (CCl₄). Methods: SD rats were intragastric with normal saline, Diammonium Glycyrrhizinate Capsules (GLX) and glycyrrhiza and pueraria fermentation composition, respectively, and treated with carbon tetrachloride to establish chronic liver injury model. The contents of liver function indexes (ALT, AST, TBIL, TP), liver fiber indexes (PLD, TGF-β₁, HA), endotoxin and inflammatory factors (LPS, TNF-α, IL-6) in serum of mice were detected by enzyme linked immunosorbent assay. Pathological changes of liver tissue were observed by light microscope and transmission electron microscope. At the same time, the intestinal flora of different treatment groups was quantitatively analyzed. Results: Compared with normal saline treatment group, treatment group glycyrrhiza and pueraria fermentation composition mice serum AST, ALT level decreased extremely significant (P<0.01). There were no significant differences in serum TBIL and TP levels in glycyrrhiza and pueraria fermentation composition treatment group before and after modeling. The results of liver fibrosis index showed that TGF-β₁ (P<0.01), PLD (P<0.01) and HA (P<0.05) in glycyrrhiza and pueraria fermentation composition protected group were significantly lower than those in normal saline control group. Compared with normal saline treatment group, there were no significant differences in serum IL-6 and LPS levels before and after modeling in glycyrrhiza and pueraria fermentation composition treatment group, while TNF-α level extremely significant decreased in glycyrrhiza and pueraria fermentation composition treatment group (P<0.01). Pathological observation showed that there were no obvious pathological changes in liver tissues in glycyrrhiza and pueraria fermentation composition and GLX treatment groups. The number of EMB, EC, KV and CD in glycyrrhiza and pueraria fermentation composition protection group decreased, while TPY and MRS increased. Conclusion: Glycyrrhiza and pueraria fermentation composition and GLX had certain protective effects on chronic liver injury induced by CCl₄ in rats, and glycyrrhiza and pueraria fermentation composition had more significant effects on liver fibrosis, reducing inflammation and endotoxin levels, and regulating intestinal flora during chronic liver injury.
- glycyrrhiza and pueraria fermentation composition,
- CCl₄,
- chronic liver injury,
- intestinal flora

FullText(HTML)

References (27)

References

[1]	李冀, 李想, 曹明明, 等. 甘草药理作用及药对配伍比例研究进展[J]. 上海中医药杂志,2019,53(7):83−87. [LI Ji, LI Xiang, CAO Mingming, et al. Research progress in pharmacological actions of liquorice and proportion of couplet medicines in combination[J]. Shanghai Journal of Traditional Chinese Medicine,2019,53(7):83−87. LI Ji, LI Xiang, CAO Mingming, et al. Research progress in pharmacological actions of liquorice and proportion of couplet medicines in combination[J]. Shanghai Journal of Traditional Chinese Medicine, 2019, 53(7): 83-87.
[2]	甘草酸制剂肝病临床应用专家共识[J]. 临床肝胆病杂志, 2016, 32(5): 844−852. Expert consensus on clinical application of glycyrrhizin preparation in the treatment of liver diseases[J]. J Clin Hepatol, 2016, 32(5): 844−852.
[3]	史晨旭, 杜佳蓉, 吴威, 等. 葛根化学成分及药理作用研究进展[J]. 中国现代中药,2021,23(12):2177−2195. [SHI Chenxu, DU Jiarong, WU Wei, et al. Advances in the study of chemical constituents and pharmacological action of Puerariae lobatae radix[J]. Modern Chinese Medicine,2021,23(12):2177−2195. SHI Chenxu, DU Jiarong, WU Wei, et al. Advances in the study of chemical constituents and pharmacological action of Puerariae lobatae radix[J]. Modern Chinese Medicine, 2021, 23(12): 2177-2195.
[4]	木盼盼, 安琪, 张彦昭, 等. 一测多评法测定葛根药材中9个异黄酮成分的含量[J]. 中国中药杂志,2019,44(22):4888−4895. [MU Panpan, AN Qi, ZHANG Yanzhao, et al. Determination of 9 isoflavonoids in Puerariae lobatae radix with quantitative analysis of multi-components by single marker[J]. China Journal of Chinese Materia Medica,2019,44(22):4888−4895. MU Panpan, AN Qi, ZHANG Yanzhao, et al. Determination of 9 isoflavonoids in Puerariae lobatae radix with quantitative analysis of multi-components by single marker[J]. China Journal of Chinese Materia Medica, 2019, 44(22) : 4888-4895.
[5]	赵月蓉, 侯碧玉, 张莉, 等. 葛根素对实验性肝损伤的治疗作用研究进展[J]. 中国新药杂志,2017,26(9):1005−1010. [ZHAO Yuerong, HOU Biyu, ZHANG Li, et al. Research progress of puerarin in the treatment of experimental liver injury[J]. Chinese Journal of New Drugs,2017,26(9):1005−1010. ZHAO Yuerong, HOU Biyu, ZHANG Li, et al. Research progress of puerarin in the treatment of experimental liver injury[J]. Chinese Journal of New Drugs, 2017, 26(9): 1005-1010.
[6]	朱振元, 罗游, 薛婧, 等. 葛根功能饮料的急性毒性及解酒护肝功效评价[J]. 食品研究与开发,2016,37(21):160−163. [ZHU Zhenyuan, LUO You, XUE Jing, et al. Acute toxicity test and sober and hepatoproctive efficacy evaluation of radix puerariae functional beverage[J]. Food Research and Development,2016,37(21):160−163. doi: 10.3969/j.issn.1005-6521.2016.21.037 ZHU Zhenyuan, LUO You, XUE Jing, et al. Acute toxicity test and sober and hepatoproctive efficacy evaluation of radix puerariae functional beverage[J]. Food Research and Development, 2016, 37(21): 160-163. doi: 10.3969/j.issn.1005-6521.2016.21.037
[7]	KAI M C, STEFANIE A, CHRISTIAN T. Role of bile acids in the gut-liver axis[J]. Journal of Hepatology,2018,68(5):1083−1085. doi: 10.1016/j.jhep.2017.11.025
[8]	WANG Rui, TANG Ruqi, LI Bo, et al. Gut microbiome, liver immunology, and liver diseases[J]. Cellular & Molecular Immunology,2021(8):4−17.
[9]	ANUPRIYA T, JUSTINE D, DAVID A B, et al. The gut-liver axis and the intersection with the microbiome[J]. Nature Reviews Gastroenterology & Hepatology,2018,15:397−411.
[10]	SIDDHARTHA S G, WANG J, PAUL J Y, et al. Intestinal barrier function and metabolic/liver diseases[J]. Liver Research,2020(4):81−87.
[11]	RYO A. Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice[J]. Microbiome,2021,9(1):188. doi: 10.1186/s40168-021-01125-7
[12]	SHARPTON S, SCHNABL B, KNIGHT R, et al. Current concepts, opportunities and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease[J]. Cell Metabolism,2011,33(1):21−32.
[13]	孟凡涛, 刘冬菊. 研究中药发酵炮制法[J]. 世界最新医学信息文摘,2018,18(10):8−9. [MENG Fantao, LIU Dongju. To study the method of fermentation of Chinese medicine[J]. World Latest Medicine Informationn (Electronic Version),2018,18(10):8−9. MENG Fantao, LIU Dongju. To study the method of fermentation of Chinese medicine[J]. World Latest Medicine Informationn (Electronic Version), 2018, 18(10): 8-9.
[14]	李艳凤, 翟梦颖, 李雨昕, 王等. 发酵法在中药研究中的应用[J]. 医学综述,2020,26(4):753−757. [LI Yanfeng, ZHAI Mengying, LI Yuxin, et al. Application of fermentation method in study of traditional Chinese medicine[J]. Medical Recapitulate,2020,26(4):753−757. doi: 10.3969/j.issn.1006-2084.2020.04.025 LI Yanfeng, ZHAI Mengying, LI Yuxin, et al. Application of fermentation method in study of traditional Chinese medicine[J]. Medical Recapitulate, 2020, 26(4): 753-757. doi: 10.3969/j.issn.1006-2084.2020.04.025
[15]	张丽霞, 高文远, 王海洋. 微生物技术在中药炮制中的应用[J]. 中国中药杂志,2012,37(24):3695−3699. [ZHANG Lixia, GAO Wenyuan, WANG Haiyang. Application of microbial technology in the processing of traditional[J]. Chinese Medicine China Journal of Chinese Materia Medica,2012,37(24):3695−3699. ZHANG Lixia, GAO Wenyuan, WANG Haiyang. Application of microbial technology in the processing of traditional[J]. Chinese Medicine China Journal of Chinese Materia Medica, 2012, 37(24): 3695-3699.
[16]	彭静, 陈曦. 滨蒿内酯对四氯化碳致小鼠急性肝损伤的保护作用研究[J]. 中国药房,2021,32(2):231−235. [PENG Jing, CHEN Xi. Study on protective effects of scoparone on acute liver injury induced by CCl₄ in mice[J]. China Pharmacy,2021,32(2):231−235. doi: 10.6039/j.issn.1001-0408.2021.02.18 PENG Jing, CHEN Xi. Study on protective effects of scoparone on acute liver injury induced by CCl₄ in mice[J]. China Pharmacy, 2021, 32(2): 231-235. doi: 10.6039/j.issn.1001-0408.2021.02.18
[17]	王昱. 红腹锦鸡肝脏结构的透射电镜观察[J]. 甘肃农业大学学报,2011,4:43−46. [WANG Yu. Transmission electron microscopical observation on the liver structure of Chroysolophus pictus[J]. Journal of Gansu Agricultural University,2011,4:43−46. doi: 10.3969/j.issn.1003-4315.2011.03.009 WANG Yu. Transmission electron microscopical observation on the liver structure of Chroysolophus pictus[J]. Journal of Gansu Agricultural University, 2011, 4: 43-46. doi: 10.3969/j.issn.1003-4315.2011.03.009
[18]	刘旭凌, 杨广越, 张玮, 等. 桃红四物汤对CCl₄诱导肝纤维化小鼠模型的干预作用及其机制[J]. 临床肝胆病杂志,2021,37(11):2563−2568. [LIU Xuling, YANG Guangyue, ZHANG Wei, et al. Therapeutic effect of Taohong Siwu decoction on a mouse model of carbon tetrachloride-induced liver fibrosis and its mechanism[J]. J Clin Hepatol,2021,37(11):2563−2568. doi: 10.3969/j.issn.1001-5256.2021.11.016 LIU Xuling, YANG Guangyue, ZHANG Wei, et al. Therapeutic effect of Taohong Siwu decoction on a mouse model of carbon tetrachloride-induced liver fibrosis and its mechanism[J]. J Clin Hepatol, 2021, 37(11). doi: 10.3969/j.issn.1001-5256.2021.11.016
[19]	张燕, 范晓翔, 章美武, 等. NLRC5 调节转化生长因子-β₁诱导的肝星状细胞活化及逆转对肝纤维化的影响[J]. 中国全科医学,2020,23(24):3051−3059. [ZHANG Yan, FAN Xiaoxiang, ZHANG Meiwu, et al. Role of NLRC5 in the activation of hepatic stellate cells induced by TGF-β₁ and reversal of hepatic fibrosis[J]. Chinese General Practice,2020,23(24):3051−3059. ZHANG Yan, FAN Xiaoxiang, ZHANG Meiwu, et al. Role of NLRC5 in the activation of hepatic stellate cells induced by TGF-β1 and reversal of hepatic fibrosis[J]. Chinese General Practice, 2020, 23(24): 3051-3059.
[20]	张永超, 毕研贞, 方萧, 等. 益生菌对慢加急性肝衰竭大鼠模型的保护作用及其机制[J]. 临床肝胆病杂志,2019,35(7):1570−1575. [ZHANG Yongchao, BI Yanzhen, FANG Xiao, et al. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. J Clin Hepatol,2019,35(7):1570−1575. doi: 10.3969/j.issn.1001-5256.2019.07.029 ZHANG Yongchao, BI Yanzhen, FANG Xiao, et al. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. J Clin Hepatol, 2019, 35(7): 1570-1575. doi: 10.3969/j.issn.1001-5256.2019.07.029
[21]	JASMOHAN S B. Alcohol, liver disease and the gut microbiota[J]. Nature Reviews Gastroenterology & Hepatology,2019,16:235−246.
[22]	NAGA S B, PATRICK M G, JASMOHAN S B. Gut microbiome and liver disease[J]. Translational Research,2017,179:49−59. doi: 10.1016/j.trsl.2016.07.005
[23]	MING Lyu, WANG Yuefei. Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota[J]. Frontiers in Microbiology,2017,8:2146. doi: 10.3389/fmicb.2017.02146
[24]	LIN Tzulung, LU Chiachen, LAI Weifan, et al. Role of gut microbiota in identification of novel TCM-derived active metabolites[J]. Protein & Cell,2021,12:394−410.
[25]	LIU Meng, YUAN Jie, HU Wenjuan, et al. Pretreatment with broad-spectrum antibiotics alters the pharmacokinetics of major constituents of Shaoyao-Gancao decoction in rats after oral administration[J]. Pharmacologica Sinica,2019,40(2):288−296. doi: 10.1038/s41401-018-0011-0
[26]	LI Yun, LIU Tianyu, YAN Chen, et al. Diammonium glycyrrhizinate protects against non-alcoholic fatty liver disease in mice through modulation of gut microbiota and restoring intestinal barrier[J]. Molecular Pharmaceutics,2018,15(9):3860−3870. doi: 10.1021/acs.molpharmaceut.8b00347
[27]	ZHANG Feng, HE Fang, LI Li, et al. Bioavailability based on the gut microbiota: A new perspective[J]. Microbiology and Molecular Biology Reviews, 2020, 84(2):19.

Supplements (0)

Cited By

Cited by

Periodical cited type(6)

1.	吴思邈，蒋浩源，安莹，张丽冕，李彭. L-赖氨酸功能化纤维素对模拟苹果汁中铅的吸附特性研究. 食品工业科技. 2024(08): 97-109 . 本站查看
2.	张琳，马悦，张悦，陆辉杰，陈子琨，刘宏生. 科教融汇及思政育人新路径——食品包装技术课程创新实验设计. 农业工程. 2024(06): 133-137 .
3.	唐蓉萍，李秀壮，朱一剑，吴贝贝，李树龙. 玉米秸秆高值化利用研究进展. 南方农业. 2024(21): 143-146 .
4.	朱颍，李力，孙冰华，马森. 淀粉可食性膜性能的研究进展. 粮食科技与经济. 2024(06): 94-102 .
5.	曾仪雯，周恩弛，黄高瓴，冯静秋，李丹，张春红. 可食性膜在食品保鲜中的应用现状及研究进展. 保鲜与加工. 2023(04): 62-67 .
6.	任晚霞，宋亭，张丽媛. 纳米纤维素-淀粉膜对草莓保鲜效果的影响. 中国食品添加剂. 2023(11): 6-11 .